Dyslipidemia in Cardiovascular Disease

Inclusion criteria

• Dyslipidemic patients with high-risk cardiovascular disease meeting more than 1 requirement below (LDL-C ≥ 100mg/dL) 1) Coronary artery disease

• diagnosed with atheroma in Coronary CT or Angiography, or SPECT positive or Treadmill test positive 2) Diabetes Mellitus 3) intervened with stent in coronary artery disease more than 1 year before 4) diagnosed with atheroma in carotid artery 5) Peripheral artery disease
• Aged 20~85 years
• Volunteers consented with participating clinical trial and submitted consent paper

Exclusion criteria

• Experimental examination at screening 1) Active liver disease or more than 2 x ULN of AST/ALT 2) Creatine Kinase > 2 x ULN 3) Creatinine > 2.5mg/dL 4) Triglycerides > 500mg/dL
• intervened with stent in coronary artery disease less than 1 year before
• Hyper-sensitive or resistant to other HMG-CoA reductase inhibitors, or experienced serious adverse events
• Patients taking dyslipidemic treatments within 4 weeks (HMG-CoA reductase inhibitors, fibrates, nicotinic acids or bile acid resins, etc.)
• As uncontrolled DM patients, HbA1c≥11% or fasting plasma glucose ≥200mg/dL
• DBP > 100mmHg, SBP > 160mmHg
• Diagnosed with myopathy
• Appear to be a risk of myopathy below

• renal impairment or prior renal dysfunction
• hypothyroidism
• genetic defects or family history of myopathy
• experienced prior muscle toxicity with taking statins or fibrates
• prior liver disease or higher intakes of alcohol
• aged over 70, and a risk of myopathy
• Women pregnant or breast-feeding
• Women capable of pregnancy without using contraceptives
• contra-indicated medically or mentally, or forbidden legally
• Enrolled to other clinical trial within 4 weeks
• Impossible to participate clinical trial according to investigator's decision